A5050508952- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Urologic and reproductive health conditions
- MRI in cancer diagnosis
- Bladder and Urothelial Cancer Treatments
- Advanced Radiotherapy Techniques
- Advanced X-ray and CT Imaging
- Cancer, Lipids, and Metabolism
- Genital Health and Disease
- Medical Image Segmentation Techniques
- Cardiac Imaging and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Advanced MRI Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Renal and Vascular Pathologies
- Anesthesia and Pain Management
- Ultrasound and Hyperthermia Applications
- Molecular Biology Techniques and Applications
- Anesthesia and Sedative Agents
- Renal cell carcinoma treatment
- AI in cancer detection
- Organ Donation and Transplantation
- COVID-19 and healthcare impacts
- Urinary Bladder and Prostate Research
University College London Hospitals NHS Foundation Trust
2019-2025
University College London
2015-2025
Royal London Hospital
2017-2023
University College Hospital
2017-2023
The Alan Turing Institute
2020
Fondazione Vincenzo Pansadoro
2020
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2013-2018
Université de Caen Normandie
2012-2018
Normandie Université
2013-2018
Cyceron
2013-2018
No AccessJournal of UrologyAdult Urology1 Aug 2015Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Histology Co-Registration Analysis Julien Le Nobin, Andrew B. Rosenkrantz, Arnauld Villers, Clément Orczyk, Fang-Ming Deng, Jonathan Melamed, Artem Mikheev, Henry Rusinek, and Samir S. Taneja NobinJulien Nobin Division Urologic Oncology, Department Urology, New York University Langone Medical Center, York,...
Although the use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance (AS) for prostate cancer is increasing interest, existing data are derived from small cohorts.We describe clinical, histological, and radiological outcomes an established AS programme, where protocol-based biopsies were omitted favour MRI-led monitoring.Data on 672 men enrolled between August 2004 November 2017 (inclusion criteria: Gleason 3 + or 4 localised cancer, presenting prostate-specific...
Objective To report medium‐term oncological outcomes in men receiving primary focal treatment with high‐intensity focused ultrasonography ( HIFU ) for prostate cancer PC a). Patients and Methods Consecutive patients a treated at two centres by six treating clinicians were assessed. submitted to either ablation or hemi‐ablation using (Sonablate 500). The objective of the study was assess outcomes, defined as overall survival, freedom from biopsy failure, any further radical after . secondary...
At present there is no standardised system for scoring the appearance of prostate on multiparametric magnetic resonance imaging (MRI) after focal ablation localised cancer. We propose a novel system, Prostate Imaging Focal Ablation (PI-FAB) score, to fill this gap. PI-FAB involves 3-point scale rating MRI sequences in sequential order: (1) dynamic contrast-enhanced sequences; (2) diffusion-weighted imaging, split into assessment high-b-value sequence first and then apparent diffusion...
To evaluate the agreement between prostate tumour volume determined using multiparametric magnetic resonance imaging (MRI) and that by histological assessment, detailed software-assisted co-registration.A total of 37 patients who underwent 3T MRI (T2-weighted [T2WI], diffusion-weighted [DWI]/apparent diffusion coefficient [ADC], dynamic contrast-enhanced [DCE] imaging) were included. A radiologist traced borders suspicious lesions on T2WI ADC assigned a suspicion score 2 5, while...
Abstract Objectives The PRECISE recommendations for magnetic resonance imaging (MRI) in patients on active surveillance (AS) prostate cancer (PCa) include repeated measurement of each lesion, and attribution a radiological progression score the likelihood clinically significant change over time. We aimed to compare with clinical who are managed using an MRI-led AS protocol. Methods A total 553 low- intermediate-risk PCa (up Gleason 3 + 4) had two or more MRI scans performed between December...
The inclusion of imaging as a triage test in diagnostic guidelines for prostate cancer (PC) has introduced visible target guiding treatment allocation and disease management. Focal therapy (FT) is promising approach with low side-effect profile treating magnetic resonance (MRI)-visible PC within limited framework guideline recommendations or clinical trials. On the basis accumulated research experience, we present systematic to FT indications ablation targets that includes findings, margin...
Focal therapy treats individual areas of tumour in non-metastatic prostate cancer patients unsuitable for active surveillance. The aim this work was to evaluate the cost-effectiveness focal versus prostatectomy and external beam radiotherapy (EBRT).A Markov cohort health state transition model with four states (stable disease, local recurrence, metastatic disease death) created, evaluating costs utilities over a 10-year time horizon diagnosed cancer. National Health Service (NHS) England...
Recurrent prostate cancer after radiotherapy occurs in one five patients. The efficacy of magnetic resonance imaging (MRI) recurrent has not been established. Furthermore, high-quality data on new minimally invasive salvage focal ablative treatments are needed. To evaluate the role MRI detection recurring and ablation treating disease. FORECAST trial was both a paired-cohort diagnostic study evaluating multiparametric (mpMRI) MRI-targeted biopsies cohort at six UK centres. A total 181...
The role of multiparametric magnetic resonance imaging (MRI) for detecting recurrent prostate cancer after radiotherapy is unclear. To evaluate MRI and MRI-targeted biopsies intraprostatic recurrence planning salvage focal ablation. FOcal RECurrent Assessment Salvage Treatment (FORECAST; NCT01883128) was a prospective cohort diagnostic study that recruited 181 patients with suspected radiorecurrence at six UK centres (2014 to 2018); 144 were included here. All underwent 5 mm transperineal...
Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends Role of the PRECISE RecommendationsFrancesco Giganti, MD1,2, Alex Kirkham, MD1, Clare Allen, Shonit Punwani, MD, PhD1,3, Clément Orczyk, PhD2,4, Mark Emberton, MD2,4, Caroline M. Moore, MD2,4Audio Available | Share Claim CREDIT
BackgroundThe optimal radiological follow-up of prostate lesions negative on magnetic resonance imaging (MRI)-targeted biopsy (MRI-TB) is yet to be optimised.ObjectiveTo present medium-term and clinical biopsy-negative lesions.Design, setting, participantsThe records for men who underwent multiparametric MRI at the UCLH one-stop clinic suspected cancer between September 2017 March 2020 were reviewed (n = 1199). Patients with Likert 4 or 5 considered 495), those a subsequent MRI-TB comprised...
We determined the early efficacy of bipolar radiofrequency ablation with a coil design for focal clinically significant localized prostate cancer visible at multiparametric magnetic resonance imaging.A prospective IDEAL phase 2 development study (Focal Prostate Radiofrequency Ablation, NCT02294903) recruited treatment-naïve patients single focus (Gleason 7 or 4 mm more Gleason 6) concordant lesion on imaging. Intervention was system (Encage™) encompassing and predefined margin using nonrigid...
Objective To undertake an early proof‐of‐concept study on a novel, semi‐automated texture‐based scoring system in order to enhance the association between magnetic resonance imaging (MRI) lesions and clinically significant prostate cancer (SPCa). Patients Methods With ethics approval, 536 volumes were generated from 20 consecutive patients who underwent multiparametric MRI (mp MRI) at time of biopsy. Volumes interest ( VOI s) included zonal anatomy segmentation suspicious for (Likert Scale...
We describe the pathological characteristics of recurrence following high intensity focused ultrasound partial ablation in men treated with salvage robot-assisted radical prostatectomy. assessed sensitivity magnetic resonance imaging before prostatectomy these men.A total 35 underwent after from 2012 to 2018. compared clinicopathological and histopathology on infield recurrence, out field disease, positive surgical margins prostatectomy.Before 55.9% had multifocal disease 47.1% Gleason 3 +...
Our objectives were to assess the safety and clinical impact of a novel, kit-based formulation <sup>68</sup>Ga-tris(hydroxypyridinone) (<sup>68</sup>Ga-THP) prostate-specific membrane antigen (PSMA) for PET/CT in guiding management patients with prostate cancer. <b>Methods:</b> Patients prospectively recruited group A (high-risk untreated cancer; Gleason score ≥ 4 + 3, or (PSA) level > 20 ng/mL stage T2c), B (biochemical recurrence eligible salvage treatment after radical prostatectomy 2...